Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

It’s prescribed for adults with Crohn’s disease or certain forms of multiple sclerosis. Tysabri has interactions with some other drugs. Examples include prednisone (Rayos) and adalimumab (Humira).

MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure ...

Sandoz and Polpharma Biologics did not immediately reveal their launch or pricing plans, but the National MS Society said it expected the drug to be ... main patents on Tysabri (natalizumab ...

The looming competition piles further pressure on Biogen, whose MS franchise is already ... Tecfidera's decline has made Tysabri Biogen's top-selling drug. Last year, Polpharma Biologics and ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...